The Claim
Patients with Graves' disease have a lower prevalence of anti-nuclear antibodies (80%) compared to patients with toxic nodular goiter (91%).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Among people with Graves' disease, 80% test positive for anti-nuclear antibodies, while 91% of those with toxic nodular goiter test positive.
See the scientific wording
Patients with Graves' disease have a lower prevalence of anti-nuclear antibodies (80%) compared to those with toxic nodular goiter (91%), suggesting thyroid autoimmunity may be associated with reduced systemic autoantibody production, though confounding factors remain unaccounted for.
In people with Graves' disease, the presence of anti-nuclear antibodies triggers a change in immune cells that reduces inflammation in the thyroid and eyes, making it less likely for other autoimmune reactions to occur elsewhere in the body.
What the research says
1 studyStudy: Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
People with Graves' disease were less likely to have anti-nuclear antibodies than those with a different type of overactive thyroid, suggesting that having one kind of autoimmune reaction might mean you're less likely to have others.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.